Eurofarma Laboratorios
Large Brazilian generics/specialty pharma (100% Brazilian-owned)
Privately held: no public share price · Brazil
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Cenobamate(Xcopri) | Approved | Sodium channels + GABA-A receptorsSmall molecule | Epilepsy Focal Onset Seizures |
Evogliptin(Suganon) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 3 | 5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule | Migraine |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
No financial reports recorded.